BNP Paribas Financial Markets
ALLO icon

BNP Paribas Financial Markets’s Allogene Therapeutics ALLO Stock Holding History

BNP Paribas Financial Markets’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118K Sell
56,759
-14,206
-20% -$31.2K ﹤0.01% 4467
2026
Q1 		$173K Sell
70,965
-829,459
-92% -$1.66M ﹤0.01% 4118
2025
Q4 		$1.23M Buy
900,424
+6,110
+0.7% +$8.06K ﹤0.01% 2953
2025
Q3 		$1.11M Buy
894,314
+15,327
+2% +$18.3K ﹤0.01% 3056
2025
Q2 		$993K Buy
878,987
+7,390
+0.8% +$9.82K ﹤0.01% 2915
2025
Q1 		$1.27M Buy
871,597
+21,939
+3% +$41.4K ﹤0.01% 2608
2024
Q4 		$1.81M Buy
849,658
+803,284
+1,732% +$1.98M ﹤0.01% 2425
2024
Q3 		$130K Buy
46,374
+39,145
+541% +$104K ﹤0.01% 3394
2024
Q2 		$16.8K Sell
7,229
-52,591
-88% -$155K ﹤0.01% 3657
2024
Q1 		$267K Sell
59,820
-63,698
-52% -$266K ﹤0.01% 3152
2023
Q4 		$396K Sell
123,518
-446,437
-78% -$1.27M ﹤0.01% 2927
2023
Q3 		$1.81M Buy
569,955
+332,660
+140% +$1.46M ﹤0.01% 1942
2023
Q2 		$1.18M Sell
237,295
-27,340
-10% -$148K ﹤0.01% 2095
2023
Q1 		$1.31M Buy
264,635
+17,847
+7% +$114K ﹤0.01% 2137
2022
Q4 		$1.55M Sell
246,788
-41,602
-14% -$385K ﹤0.01% 1907
2022
Q3 		$3.11M Buy
288,390
+256,934
+817% +$3.49M 0.01% 1638
2022
Q2 		$359K Buy
31,456
+22,315
+244% +$198K ﹤0.01% 2829
2022
Q1 		$83.3K Sell
9,141
-11,258
-55% -$117K ﹤0.01% 3414
2021
Q4 		$304K Buy
20,399
+4,958
+32% +$87.5K ﹤0.01% 3242
2021
Q3 		$397K Buy
15,441
+12,805
+486% +$304K ﹤0.01% 2833
2021
Q2 		$68.7K Sell
2,636
-4,313
-62% -$123K ﹤0.01% 3151
2021
Q1 		$245K Buy
6,949
+1,226
+21% +$41.4K ﹤0.01% 2941
2020
Q4 		$144K Sell
5,723
-6,949
-55% -$226K ﹤0.01% 3038
2020
Q3 		$478K Sell
12,672
-8,099
-39% -$305K ﹤0.01% 2241
2020
Q2 		$889K Sell
20,771
-915
-4% -$33.1K ﹤0.01% 1853
2020
Q1 		$422K Buy
21,686
+16,112
+289% +$384K ﹤0.01% 2440
2019
Q4 		$145K Sell
5,574
-1,111
-17% -$30.6K ﹤0.01% 3109
2019
Q3 		$182K Buy
6,685
+3,244
+94% +$92.4K ﹤0.01% 2799
2019
Q2 		$92.4K Buy
+3,441
New +$95.9K ﹤0.01% 3081

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Financial Markets's ALLO Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Allogene Therapeutics (ALLO) stake by 20% in Q2 2026, selling an estimated $31.2K and leaving 56,759 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #4467.

BNP Paribas Financial Markets first reported a position in ALLO in Q2 2019 and has held it in 29 quarters since. The position peaked at $3.11M in Q3 2022. 195 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • BNP Paribas Financial Markets held 56,759 shares of Allogene Therapeutics worth $118K as of Q2 2026.
  • BNP Paribas Financial Markets sold 14,206 Allogene Therapeutics shares in Q2 2026, an estimated $31.2K.
  • Allogene Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4467 holding.
  • BNP Paribas Financial Markets first reported a position in Allogene Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • BNP Paribas Financial Markets's Allogene Therapeutics position peaked at $3.11M in Q3 2022.
  • 195 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.